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stroke care would prevent stroke-related death in 25,000
patients, serious disability in 71,000, and nursing home admis-
sion in 25,000. Despite the costs associated with such a program,
the net savings in health care costs over a 20-year period would
amount to Can$12 billion. CONCLUSION: Implementing
proven stroke therapies and practices across Canada will result
in signiﬁcant improvements in both lives and health care costs.
Analyses based on this model will support national and provin-
cial stroke strategies appropriate to their needs and resources.
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OBJECTIVES: To estimate cost-effectiveness of rFVIIa com-
pared to standard care in treating ICH over an average MCO
enrollment period of two years from a third-party payer per-
spective. METHODS: A decision-analytic model estimating cost-
effectiveness of rFVIIa 80 mcg/kg compared to standard care in
treating ICH was adapted to measure cost-effectiveness over a
time horizon (enrollment period) of two years. Input parameters
were obtained from clinical trial, claims data, and published lit-
erature. Cost of rFVIIa was based on wholesale acquisition cost.
Costs were in 2006 US dollars. Outcomes included life-years and
quality-adjusted life years (QALY). In addition, population char-
acteristics were considered, including age (over/under 65) and
gender comparisons. One-way and multivariable sensitivity
analyses were conducted to assess robustness. RESULTS: Assum-
ing a cost-effectiveness threshold of $50,000 QALY, the incre-
mental cost-effectiveness ratio (ICER) showed rFVIIa to be
cost-effective compared to standard care alone ($2924/QALY
gained). Use of rFVIIa was found to be cost-effective in both the
under- and over-65 populations ($532/QALY gained and
$5323/QALY gained, respectively). Results did not differ sub-
stantially across gender. Results were robust to changes in model
parameters. CONCLUSION: Treating ICH with rFVIIa 80 mcg/
kg within an MCO is cost-effective over the average patient
enrollment period of two years compared to standard care. Due
to potential improvements in long-term clinical outcome, treat-
ment with rFVIIa may have an even greater positive impact in
health plans with a younger population.
STROKE—Methods & Concepts
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OBJECTIVES: Health policy decision makers prefer to make
decisions with accurate estimates of the burden of the target
problem and the likely outcome of various policy options. Cre-
ating these estimates involves collecting, synthesizing, and com-
municating complex data. Simulation models provide a useful
approach for integrating complex data for producing compelling
reports. This project utilized a simulation model in the produc-
tion of a legislative document reporting on the impact of
improved stroke services in Mississippi (MS). METHODS: The
research team met with various stakeholders in stroke care
within MS, to identify a target policy issue for the legislative
report. Based on interests of MS stroke researchers, advocates,
clinicians, and policy experts, we identiﬁed the following issue:
improvements in stroke care through the use of an existing
telemedicine infrastructure as a target issue, with attention to
impact on Medicaid costs. We modiﬁed the Duke Stroke Policy
Model (DSPM), a Markov model of stroke development and
outcome to incorporate MS risk factors (from the REGARDS
survey), costs (from Medicare), and current stroke services (from
the MS Stroke Report 2005). Estimates of health and economic
impacts aimed at improving stroke care were incorporated into
an illustrative legislative report. RESULTS: The DSPM-based
report was generated as above. The illustrative report has been
reviewed by stakeholders in state policy for comment. The report
is perceived as easy-to-read and informative. CONCLUSION:
Bridging the gap between evidence and policy making will
require innovative and efﬁcient approaches to linking existing
data to produce compelling reports. This application of the
DSPM provides “proof of concept” of one approach based on
the use of a general purpose simulation model of stroke. We
believe that this is a promising strategy and will work to expand
our efforts to other states and a broader range of stroke policy
issues.
STROKE—Patient-Reported Outcomes
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OBJECTIVES: To measure and compare generic and disease-
speciﬁc HRQoL in stroke survivors one to two years post hos-
pital discharge. METHODS: The SF-36 and the Stroke Impact
Scale (SIS) were administered to 33 stroke survivors. The stan-
dard gamble method was used to elicit utilities regarding stroke
health states. RESULTS: Of the 33 patients, 79% were male,
67% had mild stroke, 24% had moderate stroke, and 9% had
severe stroke; mean age was 66.9. Study participants scored sig-
niﬁcantly lower (p < 0.05) than the general population on seven
of the eight multi-item scales of the SF-36: Physical Functioning,
Role-Physical, General Health, Vitality, Social Functioning,
Role-Emotional, and Mental Health. Participants scored signiﬁ-
cantly lower (p < 0.001) than the general population on both
physical and mental health component summary measures.
Using the SIS, participants had a mean score of 57.23 on the
physical summary score. On the four component scales of the
physical summary score, participants had mean scores of: 44.14
on Strength, 50.31 on Hand Strength, 65.93 on Mobility, and
71.26 on Activities of Daily Living (ADL). Participants had mean
scores of 79.55 on Memory, 85.91 on Communication, 73.18
on Emotional, and 57.68 on Social Participation. SIS Physical
was signiﬁcantly correlated (p < 0.05) with both SF-36 physical
measures. Both the SF-36 mental component scores and Mental
Health domain measure were signiﬁcantly correlated with the SIS
measures of ADL, Memory, Communication, Emotional, and
Social Participation (p < 0.05). The mean standard gamble utility
score for all participants was 83.2. CONCLUSION: Stroke sur-
vivors one to two years post stroke had signiﬁcantly lower scores
than the general population on most of the SF-36 health domains
with the exception of bodily pain. Positive correlations with
major domains of the disease-speciﬁc SIS indicate that the SF-36
was sensitive to stroke health states. Further research with 
